Harpoon
Merck and Daiichi Sankyo Collaborate to Develop T-Cell Engager MK-6070 from Harpoon Acquisition
Merck, Daiichi Sankyo, T-cell engager, MK-6070, Harpoon Therapeutics, small cell lung cancer, DLL3, antibody-drug conjugates
Actionable Insights Powered by AI
Merck, Daiichi Sankyo, T-cell engager, MK-6070, Harpoon Therapeutics, small cell lung cancer, DLL3, antibody-drug conjugates